Last reviewed · How we verify
Gene Therapy product:vMCO-I
At a glance
| Generic name | Gene Therapy product:vMCO-I |
|---|---|
| Sponsor | Nanoscope Therapeutics Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection
- Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gene Therapy product:vMCO-I CI brief — competitive landscape report
- Gene Therapy product:vMCO-I updates RSS · CI watch RSS
- Nanoscope Therapeutics Inc. portfolio CI